Tarsus Pharmaceuticals Rings the Nasdaq Stock Market Closing Bell
Tarsus Pharmaceuticals, (Nasdaq: TARS), a leading eye care company, visits the Nasdaq MarketSite in Times Square. Tarsus just received FDA approval and announced the availability of the first and only approved therapeutic for the treatment of Demodex blepharitis – a highly prevalent eye disease affecting approximately 25 million Americans. In honor of the occasion, Bobby Azamian, MD, PhD, Chairman and CEO of Tarsus, rings the Closing Bell, alongside other executives and Board members.